英语轻松读发新版了,欢迎下载、更新

FDA will convene an advisory committee to tackle AI mental health device regulation

2025-09-11 14:36:39 英文原文

作者:Mario Aguilar

Announcement comes as concern over use of chatbots grows

Adobe

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

The Food and Drug Administration will convene experts to discuss challenges around regulating mental health products that use artificial intelligence, as a growing number of companies release chatbots powered by large language models whose output can be unpredictable. 

The move suggests the agency may soon tighten its focus on such tools.

The Nov. 6 meeting of the FDA’s Digital Health Advisory Committee (DHAC) will focus on “Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices,” according to a notice published Thursday in the Federal Register. The notice says newly released mental health products using AI pose “novel risks and, as mental health devices continue to evolve in complexity, regulatory approaches ideally will also evolve to accommodate these novel challenges.” 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Health Tech Correspondent

    Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the practice of health care and the business and policy challenges to realizing tech’s promise. He’s also the co-author of the free, twice weekly STAT Health Tech newsletter. You can reach Mario on Signal at mariojoze.13.

关于《FDA will convene an advisory committee to tackle AI mental health device regulation》的评论


暂无评论

发表评论

摘要

The FDA plans to convene experts to discuss regulatory challenges related to mental health products using artificial intelligence, as concerns grow over the unpredictable nature of AI-powered chatbots released by various companies. The meeting, scheduled for November 6, will focus on "Generative Artificial Intelligence-Enabled Digital Mental Health Medical Devices," acknowledging that new mental health tools pose novel risks and require evolving regulatory approaches.